$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How to use Rybrevant? How long does it take for resistance to develop?
2025-10-19 11:44:20
Check Details
Where can I buy the third-generation ALK inhibitor lorlatinib? What is the effect?
2025-10-19 11:44:20
Check Details
What is the dosage of lorlatinib? What are the side effects?
2025-10-19 11:44:20
Check Details
Targeted drug treatment of EGFR gene mutation lung cancer (1)
2025-10-19 11:44:20
Check Details
Lumakras (AMG510) was approved for marketing - breaking through the milestone of "undruggable" KRAS
2025-10-19 11:44:20
Check Details
FDA approves Amgen’s Lumakras: the world’s first KRAS-targeted therapy!
2025-10-19 11:44:20
Check Details
Detailed survival data and side effects of Lorlatinib!
2025-10-19 11:44:20
Check Details
How about the effect of AMG510 (Lumakras)? Where can I buy it in China?
2025-10-19 11:44:20
Check Details
What is the dosage of crizotinib? How long does it take for the side effects of crizotinib to disappear?
2025-10-19 11:44:20
Check Details
Can larotrectinib be purchased with medical insurance? What is the usage and dosage?
2025-10-19 11:44:20
Check Details
What is the dosage of rubidine? What are the side effects?
2025-10-19 11:44:20
Check Details
How effective is Poziotinib in treating lung cancer? What are the adverse reactions
2025-10-19 11:44:20
Check Details
1
2
...
3974
3975
3976
3977
3978
3979
3980
...
4152
4153
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
The Cornerstone Therapy for Adrenocortical Carcinoma and Global Guidelines Update
2
Trodelvy® (Sacituzumab Govitecan-hziy): A Life-Changing ADC for Advanced Cancers
3
A Revolutionary Targeted Therapy for Hematological Malignancies
4
A New Option for Advanced Renal Cell Carcinoma Treatment
5
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
6
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
7
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide
8
Fulvestrant (Faslodex) Breast Cancer Guide: Indications, Dosage and Safety Specifications
9
Adagrasib (Krazati): Full Guide to KRAS G12C Inhibitor for Cancer Treatment
10
Comprehensive Analysis of the Third-Generation EGFR-TKI
11
ATOMIC Study: Atezolizumab Plus Chemo Improves DFS in dMMR Stage III Colon Cancer
12
Oncology Immunotherapy vs Anti-Inflammatory Biologic: Dostarlimab vs Secukinumab - A Mechanism-Centered Comparison